Clinical Trial Update: Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of beta-glucan with a monoclonal antibody for metastatic neuroblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Anti-GD2 Monoclonal Antibody (3F8) (anti-GD2 monoclonal antibody (3F8))
• Beta Glucan (beta-glucan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED